Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @Xconomy
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Xconomy
-
Prikvačeni tweet
Sign up for our new free newsletters for industry news, insight, and analysis: https://mailchi.mp/xconomy.com/subscribe-twitter-profile …
#Xconomists#XconXpertise#XconBioRoundup#XcelerateLS#XconSD#XconSF#XconNY#XconBOS#XconSEA#XconPHIpic.twitter.com/BW5Oav6cRA
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@Merck Charts an R&D-Focused Course Starting With a $6.5B Spinoff - by@frankvinluan https://xconomy.com/new-york/2020/02/05/merck-charts-an-rd-focused-course-starting-with-a-6-5b-spinoff/ …$MRKHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@titanmedical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA - by@frankvinluan https://xconomy.com/national/2020/02/04/titan-medicals-cash-crunch-stalls-plans-to-get-surgical-robot-to-fda/ …$TMDIHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@Alphabetlnc's Verily,@SantenGlobal/@SantenUSA See Opthalmology Opportunity Via New Joint Venture - by@sarahdchttps://xconomy.com/san-francisco/2020/02/04/vertily-santen-see-opthalmology-opportunity-via-new-joint-venture/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Xconomy proslijedio/la je Tweet
$750M Fund Looks to Software Sector to Drive Future of Biotech https://xconomy.com/national/2020/02/04/750m-fund-looks-to-software-sector-to-drive-future-of-biotech/ … via
@xconomyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
[FEB. 6 PARTNER EVENT] NYCHBL presents 7th annual Healthcare Investment Trends. New this year: Big Exits in 2019, w/ NYC founders who had big exits. Use code HCVC-PARTNER for $25 discount. REGISTER: http://bit.ly/hcvc2020partner Sponsored by
@BDOhealth#HCVC2020Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@a16z's $750M Fund Looks to Software Sector to Drive Future of Biotech - by@sarahdchttps://xconomy.com/national/2020/02/04/750m-fund-looks-to-software-sector-to-drive-future-of-biotech/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Xconomy proslijedio/la je Tweet
Did you miss
#JPM2020 last month? Would you like to catch up with all the latest news & views? Click to read all the analysis from our experts who attended the event: http://bit.ly/2v1ODkt pic.twitter.com/ZGcv99FRal
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Xconomy proslijedio/la je TweetHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Xconomy proslijedio/la je Tweet
@Dan5tanton of@BioProInsider and@Xconomy asks#biopharma experts whether off-the-shelf is the way to go for#CARTcell therapy manufacture. Check out his work on allogeneic possibilities here: http://ow.ly/IF6050ycspi pic.twitter.com/aAtRBa7aaM
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our latest
#XconInsight video on the importance of small and emerging biotech companies on the leading edge of innovation in drug development is now live. Featuring@PRAHSciences:https://xconomy.com/xpertise/pra-health-sciences-data-reinvent-clinical-trial-practices/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@bmsnews,@BioMotiv Pact Leads to a New Fibrosis-Focused Startup - by@frankvinluan https://xconomy.com/new-york/2020/02/04/bristol-myers-biomotiv-pact-leads-to-a-new-fibrosis-focused-startup/ …$BMYHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@Passage_Bio Plans IPO as Three Gene Therapies Approach the Clinic - by@sarahdc https://xconomy.com/new-york/2020/02/03/passage-bio-plans-ipo-as-three-gene-therapies-approach-the-clinic/ …$PASGHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@Insmed Drug for Rare Pulmonary Disorder Meets Phase 2 Goals - by@sarahdc https://xconomy.com/new-york/2020/02/03/insmed-drug-for-rare-pulmonary-disorder-meets-phase-2-goals/ …$INSMHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
[FEB. 6 PARTNER EVENT] Where will the
#healthcare dollars flow in 2020? Hear from investment experts and#digitalhealth co-founders with big exits in 2019. Use HCVC-PARTNER for $25 off registration. REGISTER: http://bit.ly/hcvc2020partner Presented by NYCHBL & BDO Health#HCVC2020Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
United Therapeutics Drug Flunks Small Cell Lung Cancer Clinical Trial - by
@frankvinluan https://xconomy.com/national/2020/02/03/united-therapeutics-drug-flunks-small-cell-lung-cancer-clinical-trial/ …$UTHRHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy - by@frankvinluan https://xconomy.com/san-francisco/2020/01/31/aimmune-awarded-first-fda-approval-for-a-peanut-allergy-therapy/ …$AIMTHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Discovery Labs Converts ex-GSK King of Prussia Site into R&D “Colony” - by
@Dan5tantonhttps://xconomy.com/new-york/2020/02/03/discovery-labs-converts-ex-gsk-king-of-prussia-site-into-rd-colony/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Arcutis Bio Raises $159M in Upsized IPO to Test Skin Disease Drugs - by
@sarahdc https://xconomy.com/san-diego/2020/01/31/arcutis-bio-raises-159m-in-upsized-ipo-to-test-skin-disease-drugs/ …$ARQTHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Xconomy proslijedio/la je Tweet
ICYMI,
@aimmune won FDA approval Friday for#Palforzia, a peanut allergy therapy. The FDA decision covers kids 4-17 yrs.old... https://xconomy.com/san-francisco/2020/01/31/aimmune-awarded-first-fda-approval-for-a-peanut-allergy-therapy/ …$AIMTHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.